Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AXN-2510 · 1 trial · 1 indication
A DLT is defined as a toxicity occurring during the DLT observation period
AEs are defined and graded according to the NCI CTCAE version 5.0
| Arm | Type | Description |
|---|---|---|
| AXN-2510 | EXPERIMENTAL | AXN-2510 given as intravenous (IV) infusion every 3 weeks, for a maximum of 24 months of treatment or until discontinuation criteria is met. Two increasing dose levels will be tested. |
| Name | Type | Description |
|---|---|---|
| AXN-2510 | BIOLOGICAL | AXN-2510 is an antibody with PD-L1 blocking and VEGF inhibition activity in one drug. This is called a bispecific antibody, because it has 2 activities. This immuno-oncology treatment is in development for the treatment of solid tumors. AXN-2510 is differentiated from other PD-L1 and VEGF bispecific antibodies by its ability to inhibit multiple VEGF molecules and also increased antibody-dependent cellular cytotoxicity (ADCC) that can directly kill PD-L1-positive tumor cells. |
Inclusion Criteria: * Confirmed diagnosis of an advanced or metastatic solid tumor that is relapsed or refractory following previous therapy, and for which there is no available standard therapy. * Availability of PD-L1 Tumor Proportion Score (TPS) or Combined Positive Score (CPS); OR willingness t...
AXN-2510 is an investigational monoclonal antibody being developed for the treatment of solid tumors in adults. It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being studied for safety and efficacy in patients with advanced solid tumors.
AXN-2510 is being developed by Instil Bio, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol TIL. The company is conducting clinical trials to evaluate this investigational therapy in adult patients with advanced solid tumors.
AXN-2510 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 study is designed to assess the treatment in adult patients with advanced solid tumors.
AXN-2510 is being studied in a Phase 1 clinical trial registered as NCT07159828, titled 'A Study to Assess AXN-2510 Treatment in Adult Patients With Advanced Solid Tumors.' The trial is being conducted in the United States and enrolls adults aged 18 years and older with advanced solid tumors.
AXN-2510 is a distinct investigational monoclonal antibody developed by Instil Bio, Inc. No alternative names for this drug have been reported in the available clinical trial information. It is being studied specifically for its potential use in treating solid tumors in adults.